VERA$31.08
Chart
Performance
Key Stats
AI VERA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralVera Therapeutics (VERA) shows mixed signals. Fundamentals suggest a company in early-stage development with significant cash but no revenue. Technicals indicate a strong downtrend, while thematic positioning in biotech is favorable but requires careful consideration of clinical trial success.
Thematic
Vera Therapeutics operates in the biotechnology sector, focusing on immunological diseases, a segment with significant growth potential driven by unmet medical needs. The company's specific focus areas are promising but highly dependent on clinical trial outcomes.
Fundamental
Vera Therapeutics is a clinical-stage biotech company with substantial cash reserves to fund operations, but it has no revenue and significant operating losses, making its valuation heavily dependent on future success.
Technical
Vera Therapeutics (VERA) is experiencing a significant downtrend across various timeframes. Key technical indicators suggest continued downward pressure, with potential for further declines unless strong buying support emerges.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 75 |
| Drug Development Progress | 65 |
| Healthcare Trends | 70 |
| Regulatory Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 70 |
| Cash Flow | 10 |
| Debt Level | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 15 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 30 |
| Short-Term Oscillators | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive EPS Surprises
The company has a history of beating EPS estimates, with 7 out of the last 11 reported quarters exceeding expectations. The most recent quarter (2025 Q1) showed a positive surprise of 13.98%.
Growing Cash Position
Cash and cash equivalents have grown significantly, from $43.46M in Q4 2022 to $92.65M in Q4 2024. This indicates improving financial flexibility.
Bearish Points (8)
Consistent EPS Misses
The company has missed EPS estimates in 4 of the last 6 reported quarters, with significant misses in 2024 Q4 (-29.22%) and 2025 Q2 (-9.19%), indicating challenges in meeting earnings expectations.
No Revenue Generation
The company currently has zero reported revenue, which is a significant risk factor for a clinical-stage biotechnology company. Profitability metrics like P/S and Net Margin are consequently zero.
Calendar
August 2025
7
Next Earnings Date
H: $0.69
A: $-0.62
L: $-0.90
Profile
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Seasonals
Price Target
63.36 USD
The 39 analysts offering 1 year price forecasts for VERA have a max estimate of 100.00 and a min estimate of 23.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor with an approved IgA nephropathy (IgAN) drug (Tarpeyo/Kinpeygo), directly addressing VERA's primary target market.
Weight: 95
Direct competitor with an FDA-approved IgA nephropathy (IgAN) drug (Filspari), placing it in direct competition for market share.
Weight: 92
Major pharmaceutical company actively developing atrasentan for IgA nephropathy, a key competitor pipeline asset acquired through Chinook Therapeutics.
Weight: 88
Developing sibeprenlimab for IgA nephropathy, representing another significant pipeline competitor in the same therapeutic area.